Encompass Health Corporation $EHC Shares Purchased by Aberdeen Group plc

Aberdeen Group plc raised its holdings in shares of Encompass Health Corporation (NYSE:EHC) by 0.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 350,909 shares of the company’s stock after buying an additional 1,184 shares during the period. Aberdeen Group plc owned about 0.35% of Encompass Health worth $43,032,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Invesco Ltd. lifted its position in Encompass Health by 5.1% during the first quarter. Invesco Ltd. now owns 5,818,783 shares of the company’s stock valued at $589,326,000 after buying an additional 282,532 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in Encompass Health by 25.6% during the first quarter. T. Rowe Price Investment Management Inc. now owns 2,080,918 shares of the company’s stock valued at $210,756,000 after buying an additional 424,691 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Encompass Health by 5.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,871,581 shares of the company’s stock worth $189,549,000 after purchasing an additional 93,992 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Encompass Health by 13.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,822,376 shares of the company’s stock worth $184,571,000 after purchasing an additional 211,707 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. lifted its position in shares of Encompass Health by 11.9% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,541,477 shares of the company’s stock worth $156,121,000 after purchasing an additional 163,400 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently commented on EHC. Weiss Ratings reissued a “buy (b+)” rating on shares of Encompass Health in a research report on Wednesday, October 8th. KeyCorp boosted their target price on shares of Encompass Health from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Bank of America boosted their target price on shares of Encompass Health from $145.00 to $160.00 and gave the stock a “buy” rating in a research report on Wednesday, September 10th. UBS Group boosted their target price on shares of Encompass Health from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, October 2nd. Finally, Truist Financial boosted their target price on shares of Encompass Health from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to data from MarketBeat, Encompass Health has an average rating of “Buy” and a consensus target price of $139.86.

Encompass Health Stock Down 0.9%

Shares of NYSE:EHC opened at $122.02 on Monday. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.76. The company has a fifty day simple moving average of $122.73 and a 200 day simple moving average of $116.61. The firm has a market cap of $12.29 billion, a PE ratio of 23.88, a price-to-earnings-growth ratio of 2.14 and a beta of 0.93. Encompass Health Corporation has a 12-month low of $87.85 and a 12-month high of $127.86.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Wednesday, March 16th. The company reported $0.93 earnings per share (EPS) for the quarter. The business had revenue of $136.30 million during the quarter. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. On average, equities research analysts anticipate that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Encompass Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Wednesday, October 1st will be issued a $0.19 dividend. The ex-dividend date of this dividend is Wednesday, October 1st. This is an increase from Encompass Health’s previous quarterly dividend of $0.17. This represents a $0.76 annualized dividend and a yield of 0.6%. Encompass Health’s dividend payout ratio is currently 14.87%.

Insiders Place Their Bets

In other Encompass Health news, EVP Patrick William Tuer sold 1,020 shares of the company’s stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $123.59, for a total value of $126,061.80. Following the completion of the sale, the executive vice president directly owned 18,846 shares of the company’s stock, valued at approximately $2,329,177.14. This represents a 5.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.10% of the stock is owned by insiders.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.